BridgeBio Pharma Total Assets 2018-2024 | BBIO

BridgeBio Pharma total assets from 2018 to 2024. Total assets can be defined as the sum of all assets on a company's balance sheet.
BridgeBio Pharma Annual Total Assets
(Millions of US $)
2023 $546
2022 $623
2021 $1,013
2020 $704
2019 $632
2018 $465
2017 $0
BridgeBio Pharma Quarterly Total Assets
(Millions of US $)
2024-06-30 $794
2024-03-31 $849
2023-12-31 $546
2023-09-30 $655
2023-06-30 $504
2023-03-31 $626
2022-12-31 $623
2022-09-30 $729
2022-06-30 $862
2022-03-31 $813
2021-12-31 $1,013
2021-09-30 $782
2021-06-30 $1,081
2021-03-31 $1,093
2020-12-31 $704
2020-09-30 $788
2020-06-30 $905
2020-03-31 $990
2019-12-31 $632
2019-09-30 $641
2019-06-30 $0
2019-03-31 $0
2018-12-31 $0
2018-09-30 $0
2017-12-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $4.791B $0.009B
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.902B 7.10
Dr Reddy's Laboratories (RDY) India $12.399B 18.57
Bausch Health Cos (BHC) Canada $3.597B 2.61
Amphastar Pharmaceuticals (AMPH) United States $2.469B 13.82
Supernus Pharmaceuticals (SUPN) United States $1.872B 377.44
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Personalis (PSNL) United States $0.270B 0.00
Assembly Biosciences (ASMB) United States $0.107B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00